ALX ONCOLOGY HOLDINGS INC Income (Loss) from Continuing Operations, Per Diluted Share
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$3.03 per share for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2023-03-09
- ALX ONCOLOGY HOLDINGS INC income (loss) from continuing operations, per diluted share for fiscal 2022 was -$3.03.
- ALX ONCOLOGY HOLDINGS INC income (loss) from continuing operations, per diluted share for fiscal 2021 was -$2.07.
- ALX ONCOLOGY HOLDINGS INC income (loss) from continuing operations, per diluted share for fiscal 2020 was -$2.76.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|
| 2022-12-31 | -$3.03 10-K · filed 2023-03-09 |
| 2021-12-31 | -$2.07 10-K · filed 2023-03-09 |
| 2020-12-31 | -$2.76 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |